Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30386054 | 0.73 | ALDH1A1 (0.58) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| SCHEMBL29039486 | 0.73 | ALDH1A1 (0.58) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| SCHEMBL10654946 | 0.73 | KDM4E (0.57) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| SCHEMBL31427032 | 0.71 | ALDH1A1 (0.55) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| SCHEMBL26094704 | 0.70 | ALDH1A1 (0.54) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| SCHEMBL31104226 | 0.70 | KDM4E (0.54) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| Hydrochloric Acid SCHEMBL31427020 | 0.70 | ALDH1A1 (0.54) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| SCHEMBL30201856 | 0.70 | ALDH1A1 (0.54) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| SCHEMBL13659509 | 0.69 | ALDH1A1 (0.53) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 | |
| SCHEMBL3977212 | 0.68 | ALDH1A1 (0.51) | ALDH1A1KDM4EHSD17B10HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-1833803-A4 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1833803-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP3, CASP2, CASP5 | ALDH1A1 1221/4885KDM4E 3062/4885HSD17B10 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.